World Lung Cancer Day: New therapies, novel combinations confer benefit
Click Here to Manage Email Alerts
World Lung Cancer Day will be held Aug. 1.
The observance is intended to raise awareness about the impact of lung cancer.
In conjunction with World Lung Cancer Day, Healio presents the following important updates in treatment, research and screening.
1. Lung cancer risk remains high among certain individuals for whom screening is not recommended. Read more.
2. Adagrasib (MRTX849, Mirati Therapeutics) demonstrated promising efficacy for pretreated patients with advanced or metastatic non-small cell lung cancer who harbor KRASG12C mutations. Read more.
3. Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced NSCLC and high PD-L1 expression. Read more.
4. The combination of pembrolizumab (Keytruda, Merck) and ramucirumab (Cyramza, Eli Lilly) benefited certain patients with immunotherapy-resistant advanced NSCLC. Read more.
5. A substantial proportion of patients with resected early NSCLC who consented to an adjuvant therapy screening trial did not receive adequate lymph node dissection or adjuvant chemotherapy. Read more.
6. A randomized phase 3 trial designed to evaluate tiragolumab (Genentech/Roche) plus atezolizumab (Tecentriq, Genentech/Roche) for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS. Read more.
7. Sex, age and smoking history may determine which patients with NSCLC derive the most benefit from immunotherapy. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts